Intrexon Corporation (XON) Set to Announce Quarterly Earnings on Tuesday
Intrexon Corporation (NYSE:XON) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Intrexon Corporation (NYSE:XON) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.42) earnings per share. On average, analysts expect Intrexon Corporation to post $-0.84 EPS for the current fiscal year and $-0.66 EPS for the next fiscal year.
Shares of Intrexon Corporation (NYSE:XON) opened at 16.58 on Tuesday. The stock’s market cap is $2.00 billion. Intrexon Corporation has a one year low of $16.11 and a one year high of $32.90. The firm has a 50-day moving average of $18.55 and a 200-day moving average of $20.90.
In related news, CEO Randal J. Kirk bought 132,625 shares of the company’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $18.85 per share, with a total value of $2,499,981.25. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert B. Shapiro bought 2,850 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were bought at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the transaction, the director now owns 43,157 shares in the company, valued at approximately $755,247.50. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 144,569 shares of company stock worth $2,719,429. Insiders own 56.30% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.